EPCS Setup

Version 14.8


EPCS requires certain areas in OP to be setup before electronic prescribing of controlled substances can be enabled.  These areas are described below.

Provider Set-up 

To enable EPCS for a provider, the provider's Federal DEA number must be entered in the Staff/Provider Directory in the Federal DEA# field.  This is a required field.  In addition OP includes the NADEAN # field in the Staff Directory (under the Provider Info tab).  If providers in your practice have been issued a Narcotics DEA (NADEAN) number, you must add their NADEAN number to the NADEAN # field in their profile in the Staff Directory.

Utilities > Manage Practice > Staff/Provider Directory

Logical Access Control (LAC) 

Utilities > Manage Practice > EPCS Access Control

The LAC is configuring providers (who have completed the IDP process) in OP as either active or inactive. This is a two-step process which requires a user with System Administrator permissions and other than the provider being activated or deactivated open the LAC.  Any provider with EPCS credentials may perform the second step by entering their passphrase and the PIN number from their token.  

Only System Administrators can access LAC. This must be a user other than the provider being activated/deactivated.
  1. Click on Utilities.
  2. Select Manage Practice.
  3. Select EPCS Access Control. This is OP functionality that enables System Administrators to set LAC for providers. This menu item is only visible to System Administrators. 


OP launches the EPCSGold web page in a separate browser window. 

  1. Select a provider to activate.
  2. Enter the NPI Number in the Enter NPI field for the provider who will be entering their passphrase and PIN from their token (this can be any provider with credentials, including the provider being activated/deactived).
  3. Validate the provider's NPI Number by clicking Validate.
  4. Have the provider enter the token they will be using for EPCS prescriptions.   
  5. Have the provider enter their Passphrase and PIN from the token.
  6. Click Authorize.

Provider Dashboard

Utilities > Manage Clinical Features > EPCS Prescriber Dashboard

The Provider Dashboard allows providers to manage their Passphrase and the authentication tokens assigned to them. Tokens include:

  • Hard token -- a device that generates authentication codes regularly and is associated with the EPC prescriber's account
  • Soft token -- similar to a hard token but rather than use an external token it is an application that runs on a device (such as a mobile phone or tablet)
  • Biometric authentication -- physical data that is unique to the provider (such as a fingerprint)
  1. Open the EPCS Prescriber Dashboard.

OP launches the EPCSGold web page in a separate browser window. The NPI Number is pre-populated.

  1. Enter your Passphrase. The EPCSGold web page displays the Token and One Time Password (OTP) fields.

To manage your Passphrase:

  1. Select Profile.
  2. Click Change EPCS Passphrase.
  3. Select token and enter your PIN.
  4. Enter your old Passphrase and then enter a new Passphrase to replace the old one. 

To manage your token(s):

  1. Select the Tokens tab.
  2. Select your token. This is only necessary if you have more than one token (such as a hard token and a soft token). The system defaults to the last token you selected.
  3. Enter the PIN that your selected token is currently displaying in the OTP field. The EPCSGold web site displays a list of tokens associated with the user.
  4. Activate, deactivate, add, or remove tokens as necessary.  

Prescription Monitoring Program (PMP)

The Coded Values window allows you to set up a link in the Prescription Writer window to the PMP web site for your state.

  1. Select Online Resource Location under Code Table Purpose.  
  2. Click the Plus button to add a new record.
  3. Enter the URL under Description.
  4. Enter "PMP" under Guidelines / Other Data.

The hyperlink to your PMP and field to document any confirmation number provided can be found on the Prescription Writer once a Schedule II-V drug has been selected.